Copyright © Inderes 2011 - present. All rights reserved.

Oriola

0,923

 

EUR

 

-1,18 %

OKDBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

7.624 investorer følger denne virksomhed
-1,18%
-1,81%
-2,43%
-3,85%
-0,97%
-15,17%
-10,56%
-54,19%
-56,05%
-49,82%
www.oriola.com/investors

Oriola is a pharmaceutical group with a special focus on the distribution of pharmaceuticals to other companies in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest presence is in the Nordic and Baltic countries. The head office is located in Espoo.

P/E (adj.) (24e)
24,64
EV/EBIT (adj.) (24e)
4,02
P/B (24e)
1,06
Udbytteafkast, % (24e)
8,67 %
Kursmål
1.00 EUR
Anbefaling
Akkumulér
Opdateret
31.10.2024
NASDAQ Helsinki
OKDBV
Daglig lav / høj pris
0,92 / 0,933 EUR
Markedsværdi
167,51 mio. EUR
Aktieomsætning
19,78 t EUR
Volumen
21 t
Business risk
Valuation risk
Current
Previous

Analytiker

Rauli Juva
Rauli Juva
Analytiker

Seneste videoer

Oriola-KD Oyj, Q3'24
30.10.2024
Oriola Q2’24: Sales growth in both segments
18.07.2024
Oriola-KD Oyj, Q2'24
18.07.2024

Finanskalender

Årsrapport
04.03.2025
Generalforsamling
02.04.2025
Delårsrapport
29.04.2025
Delårsrapport
18.07.2025
Delårsrapport
30.10.2025

Resultatopgørelse

20202021202220232024e2025e2026e2027e
Omsætning1.800,81.882,41.841,41.493,81.685,91.776,71.862,31.952,0
vækst-%4,6 %4,5 %-2,2 %-18,9 %12,9 %5,4 %4,8 %4,8 %
EBITDA63,165,468,630,127,726,728,130,2
EBIT (adj.)21,026,334,516,721,824,025,527,0
EBIT20,420,540,2-5,314,116,017,519,0
Overskud før skat14,314,735,4-17,61,210,516,518,6
Netto indkomst11,311,327,4-20,7-0,58,213,815,4
EPS (adj.)0,070,090,120,010,040,080,110,12
vækst-%-9,6 %44,4 %26,9 %-94,1 %434,6 %112,5 %38,5 %8,2 %
Udbytte0,030,040,060,070,080,090,100,06
Udbytte ratio48,2 %64,2 %39,7 %-61,2 %-3.085,9 %199,2 %131,9 %75,0 %

Lønsomhed og afkast på kapital

20202021202220232024e2025e2026e2027e
EBITDA-%3,5 %3,5 %3,7 %2,0 %1,6 %1,5 %1,5 %1,5 %
EBIT-% (adj.)1,2 %1,4 %1,9 %1,1 %1,3 %1,4 %1,4 %1,4 %
EBIT-%1,1 %1,1 %2,2 %-0,4 %0,8 %0,9 %0,9 %1,0 %
ROE6,9 %5,8 %12,4 %-10,4 %-0,3 %5,3 %9,1 %10,4 %
ROI5,0 %4,6 %10,2 %-3,1 %3,1 %6,7 %9,6 %10,6 %

Værdiansættelse

20202021202220232024e2025e2026e2027e
Aktiekurs (EUR)1,902,011,720,920,920,920,920,92
Aktier181,3181,3181,3181,3181,3181,3181,3181,3
Markedsværdi344,5364,5311,9166,8167,3167,3167,3167,3
Enterprise value471,6465,3288,2103,587,783,791,2102,0
EV/S0,30,20,20,10,10,00,00,1
EV/EBITDA7,57,14,23,43,23,13,23,4
EV/EBIT (adj.)22,517,78,46,24,03,53,63,8
EV/EBIT23,122,77,2-6,25,25,25,4
P/E (adj.)29,121,314,4131,324,611,68,47,7
P/E30,632,311,4--20,412,210,9
P/B2,01,71,41,01,11,11,11,1
P/S0,20,20,20,10,10,10,10,1
Udbytteprocent1,6 %2,0 %3,5 %7,6 %8,7 %9,8 %10,8 %6,9 %
Equity ratio14,5 %19,8 %23,5 %18,3 %16,9 %15,8 %15,5 %14,6 %
Gearing ratio74,9 %46,5 %-10,5 %-12,0 %-21,8 %-25,4 %-20,8 %-13,8 %

Kvartalsdata

Q4/232023Q1/24Q2/24Q3/24Q4/24e2024eQ1/25eQ2/25e
Omsætning386,51.493,8375,1439,5424,4446,91.685,9
EBITDA8,330,16,78,64,97,527,7
EBIT5,3-5,33,75,70,24,514,1
Overskud før skat-0,8-17,6-2,02,8-2,22,51,2
Netto indkomst-2,7-20,7-2,31,9-1,91,9-0,5
Login in to make your own estimates and see other investors estimates.
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Oriola Q2’24: Sales growth in both segments
Video af
Rauli Juva

Oriola Q2’24: Sales growth in both segments

Oriola’s Q2 earnings were quite in line with our estimates and the guidance for the whole year of 2024 remained unchanged. The joint venture company in Sweden performed better than we expected after two very weak quarters. CEO Katarina Gabrielson comments on the Q2 result in this interview.

Oriola